Login to Your Account



SPRINGTIME FOR EUROPEAN BIOTECH?

Allergy firm Circassia raises $334M in new UK biotech IPO record

By Cormac Sheridan
Staff Writer

Thursday, March 13, 2014
Circassia Pharmaceuticals plc created a new high-water mark for UK biotech by pricing its initial public offering (IPO) on the London Stock Exchange at £3.10 per share in a transaction that grossed £200 million (US$333.6 million).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription